Aligos Therapeutics ALGS 深 沪
交易中 08-10 10:18:46 美东时间
6.30
+0.710
+12.70%
华盛通- 最 高6.30
- 今 开5.74
- 成交量 3.64万股
- 最 低 5.7301
- 昨 收 5.59
- 总市值 3898.58万
- 52周最高 13.6892
- 市盈率 静 --
- 换手率 0.59%
- 52周最低 3.98
- 委 比 -12.99%
- 总股本 618.82万
- 历史最高 937.75
- 量 比 2.42
- 振 幅 10.19%
- 历史最低 3.76
- 每 手 1
- 风险率 1.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aligos Therapeutics shares are trading higher after the company reported better-than-expected Q2 earnings results.
Aligos Therapeutics shares are trading higher after the company reported better-than-expected Q2 earnings results.
08-07 01:07
Aligos Therapeutics Q2 EPS $(0.14) Beats $(1.07) Estimate, Sales $0.000 Miss $18.243M Estimate
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(1.07) by 86.92 percent. This is a 90.85 percent increase over losses of $(1.53) per share from the same period last year. The company reported quarterly sales of $0.100 whi...
08-06 20:02
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
Aligos Therapeutics reported Q2 2026 business progress and financial results. The company strengthened its financial position with a $25M upfront payment from Amoytop for the Greater China license of pevifoscorvir sodium. Pevifoscorvir sodium achieved Breakthrough Therapy Designation in China and completed enrollment in the Phase 2 B-SUPREME study. ALG-170675, an ASO for chronic HBV, received IND approval in China. Financially, the company report...
08-06 12:00
Aligos Therapeutics Receives Upfront Payment Of $25M From Exclusive License Deal Of Pevifoscorvir Sodium In Greater China With Xiamen Amoytop; Pevifoscorvir Granted Breakthrough Therapy Designation
Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it has received the upfront payment of $25M USD from the exclusive license deal of pevifoscorvi...
07-07 04:07
Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Aligos Therapeutics announced the receipt of a $25M upfront payment from its exclusive license deal with Amoytop for pevifoscorvir sodium in Greater China. The drug was granted Breakthrough Therapy Designation by China's NMPA, enabling priority review. Aligos is eligible for up to $420M in milestones and royalties, while retaining rights in key markets like the U.S., Europe, Japan, and South Korea. CEO Lawrence Blatt highlighted the collaboration...
07-06 20:05
美股大行评级 | 瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
05-29 18:09
Lake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45
Lake Street analyst Daniel Brims initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $45.
05-29 01:18
美股大行评级 | 英伟达绩后获11家大行集体上调目标价；劳氏、ELF、Intuit、VF等惨遭多家大行下调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx药业"超配"评级，目标价从84美元升至96美元；Ascendiant Capital：维持Liqtech国际"买入"评级，目标价从4.3美元升至4.4美元
05-22 10:18
Cantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Overweight rating and announces Price Target of $20.
05-21 22:14
Why Akamai Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket
Akamai Technologies Inc (NASDAQ: AKAM) rose in pre-market trading after reporting strong Q1 results and raising FY26 sales guidance.
05-08 17:54
